Molecule Information

General Information of the Molecule (ID: Mol01293)

• Name: Cancer susceptibility 9 (CASC9) ,Homo sapiens
• Synonyms: CASC9
• Molecule Type: LncRNA
• Gene Name: CARLo-7, ENST00000518376, LINC00990, MYMLR, TCONS_00014535
• Gene ID: 101805492
• Location: chr8:75120409-75352327[-]
• Ensembl ID: ENSG00000249395
• HGNC ID: HGNC:48906

Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Drug

Approved Drug(s) 1 drug(s) in total

Doxorubicin

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Breast cancer [1]

• Resistant Disease: Breast cancer [ICD-11: 2C60.3]
• Resistant Drug: Doxorubicin
• Molecule Alteration: Expression; Up-regulation
• Experimental Note: Revealed Based on the Cell Line Data
• Cell Pathway Regulation: Cell apoptosis; Inhibition; hsa04210
• Cell Pathway Regulation: Cell invasion; Activation; hsa05200
• Cell Pathway Regulation: Cell migration; Activation; hsa04670
• Cell Pathway Regulation: Cell viability; Activation; hsa05200
• In Vitro Model: MCF-7 cells; Breast; Homo sapiens (Human); CVCL_0031
• In Vitro Model: MDA-MB-231 cells; Breast; Homo sapiens (Human); CVCL_0062
• Experiment for Molecule Alteration: RT-PCR
• Experiment for Drug Resistance: MTT assay; Flow cytometry assay
• Mechanism Description: CASC9 is upregulated in breast cancer tissues and breast cancer drug-resistant cell lines and overexpressed CASC9 may significantly increase the protein expression of EZH2.

Investigative Drug(s) 1 drug(s) in total

Lipopolysaccharide

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Disease Class: Acute lung injury [2]

• Resistant Disease: Acute lung injury [ICD-11: NB32.3Z]
• Resistant Drug: Lipopolysaccharide
• Molecule Alteration: Down-regulation; Interaction
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HSAECs; N.A.; .; N.A.
• In Vivo Model: Sepsis rat model; Rattus norvegicus
• Experiment for Molecule Alteration: Knockdown assay; qRT-PCR; Western bloting analysis; Luciferase assay; RIP experiments assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: CASC9 protects lung epithelial cells from sepsis-induced injury via regulating miR-195-5p/PDK4 axis.

References

• Ref 1: Long noncoding RNA cancer susceptibility candidate 9 promotes doxorubicin resistant breast cancer by binding to enhancer of zeste homolog 2. Int J Mol Med. 2018 Nov;42(5):2801-2810. doi: 10.3892/ijmm.2018.3812. Epub 2018 Aug 7.
• Ref 2: Down-regulation of lncRNA CASC9 aggravates sepsis-induced acute lung injury by regulating miR-195-5p/PDK4 axisInflamm Res. 2020 Jun;69(6):559-568. doi: 10.1007/s00011-020-01316-2. Epub 2020 Mar 27.